(Carbidopa + levodopa) is under clinical development by Contera Pharma and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Carbidopa + levodopa)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Carbidopa + levodopa) overview
The combination of carbidopa and levodopa (CP-012) is under development for the treatment of nocturnal symptoms and morning akinesia (movement disorders) in Parkinson's disease patients. The drug candidate is administered by the oral route in the form of tablet. The drug candidate acts by targeting L-DOPA and DDC and dopaminergic receptors (D1, D2, D3 and D4). It is based on timed release technology, OralogiK.
Contera Pharma overview
Contera Pharma that engaged in identifying and developing innovative treatments for patients suffering from movement disorders. The company is headquartered in Copenhagen, Hovedstaden, Denmark.
For a complete picture of (Carbidopa + levodopa)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.